Leading antibacterial laboratory research by integrating conventional and innovative approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group

Clinical Infectious Diseases

Volumn 64, Issue , 2017, Pages S13-S17

  Manca, Claudia ^a   Hill, Carol ^b   Hujer, Andrea M ^c,d   Patel, Robin ^e,f   Evans, Scott R ^g   Bonomo, Robert A ^c,d   Kreiswirth, Barry N ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Affairs Medical Center   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Department of Laboratory Medicine and Pathology ^*  (United States)

^f MAYO CLINIC   (United States)

^g CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

Antibacterial Resistance; Bacterial strains; Biorepository; Diagnostics and Devices; Drug testing

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ALGORITHM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOBANK; CLINICAL OUTCOME; DRUG RESPONSE; DRUG SCREENING; GENOTYPE; HUMAN; MOLECULAR DIAGNOSIS; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RESEARCH PRIORITY; HEALTH CARE PLANNING; INVENTION; LABORATORY; LEADERSHIP; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PROCEDURES; STANDARDS; WEB BROWSER;

ANTI-BACTERIAL AGENTS; BIOLOGICAL SPECIMEN BANKS; BIOMEDICAL RESEARCH; DRUG RESISTANCE, BACTERIAL; HEALTH PRIORITIES; HUMANS; INVENTIONS; LABORATORIES; LEADERSHIP; WEB BROWSER;

EID: 85033549722     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw826     Document Type: Article

References (7)

1. Chambers HF, Bartlett JG, Bonomo RA, et al. Antibacterial resistance leadership group: open for business. Clin Infect Dis 2014;58:1571-6.
2. Patel R, Tsalik EL, Petzold E, et al. Viewpoint: MASTERMIND-bringing microbial diagnostics to the clinic [manuscript published online ahead of print 7 December 2016]. Clin Infect Dis 2016. pii: ciw788.
3. Huvane J, Komarow L, Hill C, et al. Fundamentals and catalytic innovation: the Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S18-23.
4. Tsalik EL, Petzold E, Kreiswirth BN, et al. Advancing diagnostics to address antibacterial resistance: the Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S41-7.
5. Evans SR, Hujer AM, Jiang H, et al; Antibacterial Resistance Leadership Group. Rapid molecular diagnostics, antibiotic treatment decisions, and developing approaches to inform empiric therapy: PRIMERS I and II. Clin Infect Dis 2016;62:181-9.
6. Evans S, Hujer A, Jiang H, et al. Informing antibiotic treatment decisions: evaluating rapid molecular diagnostics (RMDs) to identify susceptibility and resistance to carbapenems against Acinetobacter spp. PRIMERS III [manuscript published online ahead of print 26 October 2016]. J Clin Microbiol 2016. doi:10.1128/JCM.01524-16.
7. Doi Y, Bonomo RA, Hooper DC, et al. Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S24-9.